

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
VICEPT THERAPEUTICS, INC.	11/29/2011

RECEIVING PARTY DATA

Name:	ALLERGAN, INC.
Street Address:	2525 DUPONT DRIVE
City:	IRVINE
State/Country:	CALIFORNIA
Postal Code:	92612

PROPERTY NUMBERS Total: 11

Property Type	Number
Application Number:	12788746
Application Number:	12901755
Application Number:	12901911
Application Number:	60988564
Application Number:	12272253
Application Number:	61419693
Application Number:	61419697
Application Number:	61507926
Application Number:	61443210
Patent Number:	7812049
PCT Number:	US0883774

CORRESPONDENCE DATA

Fax Number: (714)246-4249
 Phone: 714-246-4356
 Email: patents_ip@allergan.com

CH \$440.00 12788746

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.

Correspondent Name: ALLERGAN, INC.
Address Line 1: 2525 DUPONT DRIVE
Address Line 4: IRVINE, CALIFORNIA 92612

ATTORNEY DOCKET NUMBER:	VICEPT
NAME OF SUBMITTER:	Ted A. Chan, Reg. No. 46,609
Total Attachments: 2 source=VICEPT-ALLERGAN ASSIGNMENT-11-29-11#page1.tif source=VICEPT-ALLERGAN ASSIGNMENT-11-29-11#page2.tif	

PATENT ASSIGNMENT

This PATENT ASSIGNMENT ("Assignment") dated as of July 18, 2011 (the "Effective Date") is made by and between VICEPT THERAPEUTICS, INC., a corporation duly organized and existing under and by virtue of the laws of the State of Delaware, having an address of 2525 Dupont Drive, Irvine, California 92612 ("ASSIGNOR"), and ALLERGAN, INC., a corporation duly organized and existing under and by virtue of the laws of the State of Delaware, having a place of business at 2525 Dupont Drive, Irvine, California 92612 ("ASSIGNEE").

WHEREAS, ASSIGNOR desires to assign its right, title and interest in and to the issued patents and pending applications listed on Schedule I (collectively, the "Patents") to Assignee; and

WHEREAS, ASSIGNEE is desirous of receiving such right, title and interest in and to the Patents from Assignor.

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ASSIGNOR sells, assigns, transfers and sets over, and by these presents does hereby sell, assign and transfer and set over, unto ASSIGNEE, its successors, legal representatives and assigns, the entire right, title and interest, including, without limitation, the right to sue for past infringement, in, to and under the Patents and all divisions thereof; and all applications for industrial property protection, including, without limitation, all applications for patents, utility models, and designs which may hereafter be filed for the invention in any country; and

ASSIGNOR HEREBY assigns and transfers to ASSIGNEE and ASSIGNEE hereby accepts the assignment and transfer from Assignor of all of Assignor's right, title and interest throughout the world in and to the Patents, including divisionals, continuations, continuations-in-part, re-issues, and reexaminations thereof, including any other counterparts thereto worldwide; and

ASSIGNOR HEREBY authorizes and requests any official of any country or countries, whose duty it is to issue patents or other evidence or forms of industrial property protection on applications as aforesaid, to issue the same to Assignee, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

IN WITNESS WHEREOF, ASSIGNOR and ASSIGNEE each has caused this instrument to be executed by its respective duly authorized representative as of the Effective Date.

Handwritten signature
Approved
Law Department

ASSIGNOR
Vicept Therapeutics, Inc.
By: *Matthew J. Maletta*

ASSIGNEE
Allergan, Inc.
By: *Debra D. Condino*

Name: Matthew J. Maletta

Name: Debra D. Condino

Title: Vice President and Secretary

Title: Assistant Secretary

Date: November 29, 2011

Date: November 29, 2011

SCHEDULE I

Country	Application No.	Filing Date	Patent No.	Issue Date
U.S.	10/763807	22-Jan-2004	7,812,049	12-Oct-2010
U.S.	12/788746	27-May-2010		
U.S.	12/901755	11-Oct-2010		
U.S.	12/901911	11-Oct-2010		
U.S.	60/988564	16-Nov-2007		
U.S.	12/272253	17-Nov-2008		
PCT	US2008/083774	17-Nov-2008		
Australia	2008322411	17-Nov-2008		
Brazil	PI0819075-5	17-Nov-2008		
Canada	2703109	17-Nov-2008		
China	200880116406.9	17-Nov-2008		
European Patent Convention	08850846.0	17-Nov-2008		
Hong Kong	11100638.5	17-Nov-2008		
Israel	205704	17-Nov-2008		
India	1098/MUMNP/2010	17-Nov-2008		
Japan	2010-534258	17-Nov-2008		
South Korea	10-2010-7013170	17-Nov-2008		
Mexico	MX/a/2010/005331	17-Nov-2008		
U.S.	61/419693	03-Dec-2010		
U.S.	61/419697	03-Dec-2010		
U.S.	61/507926	14-Jul-2011		
U.S.	61/443210	15-Feb-2011		